




Instance: composition-en-553de2aa690a5750d1825c26ecd3f9ed
InstanceOf: CompositionUvEpi
Title: "Composition for gefitinib Package Leaflet"
Description:  "Composition for gefitinib Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8c06e066675155f873d21c2aba44f835)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - gefitinib"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Gefitinib Mylan is and what it is used for  </li>
<li>What you need to know before you take Gefitinib Mylan </li>
<li>How to take Gefitinib Mylan </li>
<li>Possible side effects  </li>
<li>How to store Gefitinib Mylan </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What gefitinib is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What gefitinib is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Gefitinib Mylan contains the active substance gefitinib which blocks a protein called  epidermal 
growth factor receptor  (EGFR). This protein is involved in the growth and spread of cancer cells. </p>
<p>Gefitinib Mylan is used to treat adults with non-small cell lung cancer. This cancer is a disease in 
which malignant (cancer) cells form in the tissues of the lung. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Gefitinib Mylan:</p>
<ul>
<li>if you are allergic to gefitinib or any of the other ingredients of this medicine (listed in 
section 6). </li>
<li>if you are breast-feeding. </li>
</ul>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Gefitinib Mylan 
- if you have ever had any other lung problems. Some lung problems may get worse during 
treatment with Gefitinib Mylan. 
- if you have ever had problems with your liver. 
- if you have ever had stomach problems (gastrointestinal perforation) </p>
<p>Tell your doctor immediately if you experience dehydration or eye problems whilst taking this 
medicine (see section 4). </p>
<p>Children and adolescents 
Gefitinib Mylan is not indicated in children and adolescents under 18 years. </p>
<p>Other medicines and Gefitinib Mylan 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines as they 
may affect the way gefitinib works:</p>
<ul>
<li>Phenytoin or carbamazepine (for epilepsy). </li>
<li>Rifampicin (for tuberculosis). </li>
<li>Itraconazole (for fungal infections). </li>
<li>Barbiturates (a type of medicine used for sleeping problems). </li>
<li>Herbal remedies containing St John s wort (Hypericum perforatum, used for depression and 
anxiety). </li>
<li>Proton-pump inhibitors, H2-antagonists and antacids (for ulcers, indigestion, heartburn and to 
reduce acids in the stomach). </li>
<li>Warfarin (a so-called oral anticoagulant, to prevent blood clots). If you are taking a medicine 
containing this active substance, your doctor may need to do blood tests more often. 
If any of the above applies to you, or if you are not sure, check with your doctor or pharmacist before 
taking Gefitinib Mylan. </li>
</ul>
<p>Pregnancy and breast-feeding 
Talk to your doctor if you are pregnant, may become pregnant or are breast-feeding. </p>
<p>It is recommended that you avoid becoming pregnant during treatment with this medicine because 
Gefitinib Mylan could harm your baby. </p>
<p>Do not take Gefitinib Mylan if you are breast-feeding. This is for the safety of your baby. </p>
<p>Driving and using machines 
You may feel weak while taking treatment with this medicine. If this happens, do not drive or use any 
tools or machines. </p>
<p>Gefitinib Mylan contains lactose<br />
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>Gefitinib Mylan contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially<br />
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<ul>
<li>The recommended dose is one 250 mg tablet per day. </li>
<li>Take the tablet at about the same time each day. </li>
<li>The tablet should be swallowed with some water, with or without food. </li>
<li>Do not take antacids (to reduce the acid level of your stomach) 2 hours before or 1 hour after 
taking Gefitinib Mylan. </li>
</ul>
<p>If you have trouble swallowing the tablet, dissolve it in half a glass of still (non-fizzy) water. Do not 
use any other liquids. Do not crush the tablet. Swirl the water until the tablet has dissolved. This may 
take up to 20 minutes. Drink the liquid straight away.<br />
To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of 
water and drink it. </p>
<p>If you take more Gefitinib Mylan than you should 
If you have taken more tablets than you should, talk to a doctor or pharmacist straight away. </p>
<p>If you forget to take Gefitinib Mylan </p>
<p>What to do if you forget to take a tablet depends on how long it is until your next dose. 
* If it is 12 hours or more until your next dose: take the missed tablet as soon as you remember. 
Then take the next dose as usual. 
* If it is less than 12 hours until your next dose: skip the missed tablet. Then take the next tablet at 
the usual time. 
Do not take a double dose (two tablets at the same time) to make up for a forgotten dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Tell your doctor immediately if you notice any of the following side effects - you may need urgent 
medical treatment: 
* Allergic reaction (common), particularly if symptoms include swollen face, lips, tongue or 
throat, difficulty to swallow, hives, nettle rash and difficulty breathing. 
* Serious breathlessness, or sudden worsening breathlessness, possibly with a cough or fever. This 
may mean that you have an inflammation of the lungs called  interstitial lung disease . This may 
affect about 1 in 100 patients taking gefitinib and can be life-threatening. 
* Severe skin reactions (rare) affecting large areas of your body. The signs may include redness, 
pain, ulcers, blisters, and shedding of the skin. The lips, nose, eyes and genitals may also be 
affected. 
* Dehydration (common) caused by long term or severe diarrhoea, vomiting (being sick), nausea 
(feeling sick) or loss of appetite. 
* Eye problems (uncommon), such as pain, redness, watery eyes, light sensitivity, changes in 
vision or ingrowing eyelashes. This may mean that you have an ulcer on the surface of the eye 
(cornea). </p>
<p>Tell your doctor as soon as possible if you notice any of the following side effects: </p>
<p>Very common (may affect more than 1 in 10 people) 
* Diarrhoea. 
* Vomiting. 
* Nausea. 
* Skin reactions such as an acne-like rash, which is sometimes itchy with dry and/or cracked skin. 
* Loss of appetite. 
* Weakness. 
* Red or sore mouth. 
* Increase of a liver enzyme known as alanine aminotransferase in a blood test; if too high, your 
doctor may tell you to stop taking this medicine. </p>
<p>Common (may affect up to 1 in 10 people) 
* Dry mouth. 
* Dry, red or itchy eyes. 
* Red and sore eyelids. 
* Nail problems. 
* Hair loss. 
* Fever. 
* Bleeding (such as nose bleed or blood in your urine). 
* Protein in your urine (shown in a urine test). 
* Increase of bilirubin and the other liver enzyme known as aspartate aminotransferase in a blood 
test; if too high, your doctor may tell you to stop taking this medicine. 
* Increase of creatinine levels in a blood test (related to kidney function). </p>
<ul>
<li>Cystitis (burning sensations during urination and frequent, urgent need to urinate). </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people) 
* Inflammation of the pancreas. The signs include very severe pain in the upper part of the 
stomach area and severe nausea and vomiting. 
* Inflammation of the liver. Symptoms may include a general feeling of being unwell, with or 
without possible jaundice (yellowing of the skin and eyes). This side effect is uncommon; 
however, some patients have died from this. 
* Gastrointestinal perforation. 
* Skin reaction on the palms of the hands and soles of the feet including tingling, numbness, pain, 
swelling or reddening (known as palmar-plantar erythrodysaesthesia syndrome or hand and foot 
syndrome). </p>
<p>Rare (may affect up to 1 in 1 000 people) 
* Inflammation of the blood vessels in the skin. This may give the appearance of bruising or 
patches of non-blanching rash on the skin. 
* Haemorrhagic cystitis (burning sensations during urination and frequent, urgent need to urinate 
with blood in the urine). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and carton or pouch after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Do not store above 30 C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Gefitinib Mylan contains<br />
- The active substance is gefitinib. Each film-coated tablet contains 250 mg of gefitinib.<br />
- The other ingredients are lactose monohydrate, microcrystalline cellulose (101), crospovidone 
(type A), povidone (K30), sodium laurilsulfate, magnesium stearate in the tablet core. The tablet 
coating contains polyvinyl alcohol (E1203), macrogol 4000 (E1521), talc (E553b), titanium dioxide 
(E171), red iron oxide (E172), yellow iron oxide (E172). </p>
<p>What Gefitinib Mylan looks like and contents of the pack 
Gefitinib Mylan tablets are brown, round, biconvex film-coated tablets with approximately 11.1 mm x 
5.6 mm of dimension and marked with  250  on one side and plain on the other. 
It comes in PVC/PVDC/Aluminium blisters in packs of 30 film-coated tablets or in 
PVC/PVDC/Aluminium perforated unit dose blisters in packs of 30x1 film-coated tablets. The blisters 
may be packed into aluminium pouches. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Mylan Pharmaceuticals Limited 
Damastown Industrial Park 
Mulhuddart, Dublin DUBLIN 
Ireland </p>
<p>Manufacturer 
Ardena Pamplona S.L. 
Pol gono Mochol <br />
C/ No in, N  1<br />
31110 No in (Navarra)<br />
Spain </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 Lietuva 
Mylan Healthcare UAB<br />
Tel: +370 5 205 1  </p>
<p>: +359 2 44 55 Luxembourg/Luxemburg 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>esk  republika 
Viatris CZ. s.r.o. 
Tel: + 420 222 004 Magyarorsz g 
Mylan EPD Kft. 
Tel.: + 36 1 465 2Danmark 
Viatris ApS 
Tlf: + 45 28 11 69 Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01 Deutschland 
Viatris Healthcare GmbH<br />
Tel: + 49 800 0700 Nederland 
Mylan BV 
Tel: + 31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti 
filiaal<br />
Tel: + 372 6363 Norge 
Viatris AS 
Tlf: + 47 66 75 33  <br />
Generics Pharma Hellas  <br />
 :  +30 210 993 6 sterreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2Espa a 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102 Polska 
Mylan Healthcare Sp. z.o.o. 
Tel.: + 48 22 546 64 France 
Viatris Sant<br />
T l: +33 4 37 25 75 Portugal 
Mylan, Lda. 
Tel: + 351 214 127 Hrvatska 
Mylan Hrvatska d.o.o. <br />
Tel: +385 1 23 50 Rom nia 
BGP Products SRL 
Tel: +40 372 579 Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63  sland 
Icepharma hf. 
Simi: + 354 540 8Slovensk  republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Mylan Italia S.r.l 
Tel: + 39 02 612 46Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9<br />
Varnavas Hadjipanayis Ltd 
 : + 357 2220 7Sverige 
Viatris AB<br />
Tel: + 46 (0)8 630 19 Latvija 
Mylan Healthcare SIA 
Tel: +371 676 055 United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-553de2aa690a5750d1825c26ecd3f9ed
InstanceOf: CompositionUvEpi
Title: "Composition for gefitinib Package Leaflet"
Description:  "Composition for gefitinib Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8c06e066675155f873d21c2aba44f835)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - gefitinib"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Gefitinib Mylan 
3. Sådan skal du tage Gefitinib Mylan 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What gefitinib is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What gefitinib is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Gefitinib Mylan indeholder det aktive stof gefitinib. Gefitinib blokerer et protein, der kaldes EGFR 
(epidermal vækstfaktorreceptor). Dette protein er involveret i vækst og spredning af kræftceller. </p>
<p>Gefitinib Mylan bruges til at behandle voksne med ikke-småcellet lungekræft. Ved denne form for 
kræftsygdom dannes der ondartede (kræft)celler i lungevævet. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Gefitinib Mylan: 
- 
hvis du er allergisk over for gefitinib eller et af de øvrige indholdsstoffer (angivet i punkt 6). 
- 
hvis du ammer. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Gefitinib Mylan 
- 
hvis du nogensinde har haft andre problemer med lungerne. Nogle lungeproblemer kan blive 
værre under behandling med Gefitinib Mylan. 
- 
hvis du nogensinde har haft problemer med din lever. 
- 
hvis du nogensinde har haft problemer med din mave (gastrointestinal perforation) </p>
<p>Fortæl det straks til lægen, hvis du oplever dehydrering eller øjenproblemer, mens du tager denne 
medicin (se punkt 4).  </p>
<p>Børn og unge 
Gefitinib Mylan er ikke beregnet til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Gefitinib Mylan 
Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt anden 
medicin eller planlægger at bruge anden medicin. </p>
<p>Hvis du tager nogen af disse lægemidler, skal du især huske at fortælle det til din læge eller på 
apoteket, da andre lægemidler kan ændre den måde, som gefitinib virker på: 
- 
Phenytoin eller carbamazepin (mod epilepsi) 
- 
Rifampicin (mod tuberkulose) 
- 
Itraconazol (mod svampeinfektion) 
- 
Barbiturater (en type af medicin, der bruges mod søvnproblemer) 
- 
Naturlægemidler, som indeholder perikon (Hypericum Perforatum, mod depression og angst) 
- 
Protonpumpe-hæmmere, H2-antagonister og antacida (mod mavesår, sure opstød, halsbrand og 
til at mindske syre i maven). 
- 
Warfarin (et såkaldt oralt antikoagulationsmiddel, til forebyggelse af blodpropper). Hvis du 
tager et lægemiddel, der indeholder dette aktive stof, kan det være, at din læge vil tage 
blodprøver oftere end normalt. 
Hvis et eller flere af ovennævnte punkter gælder for dig, eller hvis du er i tvivl, skal du spørge din 
læge eller på apoteket, før du tager Gefitinib Mylan. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Det anbefales, at du undgår at blive gravid, og/eller at du ammer, mens du er i behandling med 
Gefitinib Mylan, fordi Gefitinib Mylan kan skade dit barn. </p>
<p>Tag ikke Gefitinib Mylan, hvis du ammer. Dette er af hensyn til dit barns sikkerhed. </p>
<p>Trafik- og arbejdssikkerhed 
Du kan føle dig svag, mens du får behandling med denne medicin. Hvis dette sker, må du ikke føre 
motorkøretøj eller bruge værktøj og maskiner. </p>
<p>Gefitinib Mylan indeholder lactose 
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>
<p>Gefitinib Mylan indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<ul>
<li>
<p>Den sædvanlige dosis er én tablet på 250 mg daglig. </p>
</li>
<li>
<p>Tag tabletten på ca. samme tidspunkt hver dag. </p>
</li>
<li>
<p>Tabletten skal synkes med vand, med eller uden mad. </p>
</li>
<li>
<p>Tag ikke antacida (for at mindske syre i din mave) 2 timer før og 1 time efter du tager Gefitinib 
Mylan. </p>
</li>
</ul>
<p>Hvis du har problemer med at sluge tabletten, kan den opslæmmes i et halvt glas vand (uden brus). 
Brug ikke andre væsker. Knus ikke tabletten. Sving forsigtigt glasset rundt, indtil tabletten er 
opslæmmet. Dette kan tage op til 20 minutter. Drik væsken med det samme. 
For at være sikker på, at du har drukket al medicinen, skylles glasset omhyggeligt med et halvt glas 
vand, som drikkes. </p>
<p>Hvis du har taget for mange Gefitinib Mylan tabletter 
Kontakt din læge eller apoteket straks, hvis du har taget flere tabletter end du må. </p>
<p>Hvis du glemmer at tage Gefitinib Mylan 
Hvis du har glemt at tage en tablet, skal du gøre som beskrevet nedenfor (afhængig af hvor længe, der 
er til næste dosis): </p>
<ul>
<li>
<p>Hvis der er 12 timer eller mere til din næste dosis: Tag den glemte tablet, så snart du kommer i 
tanke om det. Tag den næste dosis på samme tid, som du plejer. </p>
</li>
<li>
<p>Hvis der er mindre end 12 timer til din næste dosis: Spring den glemte tablet over, og tag den 
næste tablet på samme tid, som du plejer. 
Du må ikke tage en dobbeltdosis (to tabletter på samme tid) som erstatning for den glemte tablet. </p>
</li>
</ul>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det straks til din læge, hvis du oplever en af følgende bivirkninger - det kan være, du 
behøver akut medicinsk behandling: </p>
<ul>
<li>
<p>Allergisk reaktion (almindelig), specielt hvis du får hævet ansigt, læber, tunge eller hals, du har 
svært ved at synke, nældefeber og har svært ved at trække vejret. </p>
</li>
<li>
<p>Svær åndenød eller pludselig forværring af åndenød, muligvis med hoste og feber. Dette kan 
betyde, at du har en form for betændelse i lungerne, som kaldes ’interstitiel lungesygdom’. Dette 
kan påvirke ca. 1 ud af 100 patienter, der tager gefitinib og kan være livstruende. </p>
</li>
<li>
<p>Alvorlige hudreaktioner (sjælden) på store dele af kroppen. Dette kan også omfatte rødme, 
smerter, sår, blister og afskalning af huden. Læberne, næsen, øjnene og kønsorganerne kan også 
være påvirkede. </p>
</li>
<li>
<p>Dehydrering (almindelig) som følge af længerevarende diarré, opkastning, kvalme eller 
appetitløshed. </p>
</li>
<li>
<p>Øjenproblemer (ikke almindelig), såsom smerte, røde øjne, øjne der løber i vand, lysfølsomhed, 
forandret syn eller indgroede øjenvipper. Dette kan betyde, at du har et sår på overfladen af øjet 
(hornhinden). </p>
</li>
</ul>
<p>Fortæl hurtigst muligt din læge, hvis du lægger mærke til en af følgende bivirkninger: </p>
<p>Meget almindelig (kan påvirke mere end 1 ud af 10 patienter) </p>
<ul>
<li>
<p>Diarré. </p>
</li>
<li>
<p>Opkastning. </p>
</li>
<li>
<p>Kvalme. </p>
</li>
<li>
<p>Hudreaktioner såsom akne-lignende udslæt, som til tider er kløende og med tør og/eller 
sprukken hud. </p>
</li>
<li>
<p>Appetitmangel. </p>
</li>
<li>
<p>Svaghed. </p>
</li>
<li>
<p>Rød eller øm mund. </p>
</li>
<li>
<p>Forøget antal leverenzymer, som kaldes alanin-aminotransferase, ved en blodprøve; hvis antallet 
er for højt, vil din læge muligvis fortælle dig, at du skal stoppe med at tage dette lægemiddel. </p>
</li>
</ul>
<p>Almindelig (kan påvirke op til 1 ud af 10 patienter) </p>
<ul>
<li>
<p>Tør mund. </p>
</li>
<li>
<p>Tørre, røde og kløende øjne. </p>
</li>
<li>
<p>Røde og ømme øjenlåg. </p>
</li>
<li>
<p>Negleproblemer. </p>
</li>
<li>
<p>Hårtab. </p>
</li>
<li>
<p>Feber. </p>
</li>
<li>
<p>Blødning (såsom næseblod eller blod i urinen). </p>
</li>
<li>
<p>Protein i urinen (ses ved en urintest). </p>
</li>
<li>
<p>Forhøjet niveau af bilirubin og det andet leverenzym, som kaldes aspartat-aminotransferase, i en 
blodprøve; hvis antallet er for højt, vil din læge muligvis fortælle dig, at du skal stoppe med at 
tage dette lægemiddel. </p>
</li>
<li>
<p>Forhøjet mængde af stoffet kreatinin i en blodprøve (hænger sammen med nyrefunktionen). </p>
</li>
<li>
<p>Blærebetændelse (hyppig, sviende vandladning og pludselig vandladningstrang). </p>
</li>
</ul>
<p>Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>Betændelse (inflammation) i bugspytkirtlen. Tegn herpå er blandt andre meget stærke smerter i 
området ved den øverste del af maven, stærk kvalme og opkastning. </p>
</li>
<li>
<p>Betændelse (inflammation) i leveren. Symptomer herpå kan blandt andet være generel 
utilpashed med eller uden mulig gulsot (gullig hud og øjne). Denne bivirkning er ikke 
almindelig, men nogle patienter er døde af den. </p>
</li>
<li>
<p>Gastrointestinel perforation. </p>
</li>
<li>
<p>Hudreaktion på håndfladerne og på fodsålerne, der kan vise sig som prikken, følelsesløshed, 
smerter, hævelse eller rødme (kendt som palmoplantar erytrodysæstesi-syndrom eller hånd- og 
fodsyndrom). </p>
</li>
</ul>
<p>Sjælden (kan påvirke op til 1 ud af 1 000 personer) </p>
<ul>
<li>
<p>Betændelse (inflammation) i hudens blodkar. Det kan fremtræde som blå mærker eller plettet 
hududslæt, der ikke forsvinder ved fingertryk. </p>
</li>
<li>
<p>Hæmoragisk blærebetændelse (blærebetændelse med blod i urinen). </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. </p>
<p>Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden 
af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisterpakningen og kartonen eller posen efter 
EXP. Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Gefitinib Mylan indeholder:</h2>
<h2>Aktivt stof: gefitinib. Hver filmovertrukken tablet indeholder 250 mg gefitinib.</h2>
<p>Øvrige indholdsstoffer: lactosemonohydrat; mikrokrystallinsk cellulose (101), crospovidon 
(type A), polyvidon (K30), natriumlaurilsulfat, magnesiumstearat i tabletkerne. 
Tabletovertrækket indeholder polyvinylalkohol (E1203), macrogol 4000 (E1521), talcum 
(E553b), titandioxid (E171), jernoxid, rød (E172), jernoxid, gul (E172). </p>
<p>Udseende og pakningstørrelser 
Gefitinib Mylan er en rund, brun, bikonveks, filmovertrukket tablet med dimensionerne ca. 11,1 mm × 
5,6 mm og mærket med “250" på den ene side og uden mærkning på den anden. 
Den findes i blisterpakninger i PVC/PVDC/Aluminium med 30 filmovertrukne tabletter eller i 
perforerede enkeltdosisblisterpakninger i PVC/PVDC/Aluminium med 30×1 filmovertrukne tabletter. 
Blisterpakningerne kan pakkes ind i aluminiumsposer. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Mylan Pharmaceuticals Limited 
Damastown Industrial Park<br />
Mulhuddart, Dublin 15<br />
DUBLIN 
Irland </p>
<p>Fremstiller 
Ardena Pamplona S.L. 
Polígono Mocholí 
C/ Noáin, Nº 1 
31110 Noáin (Navarra) 
Spanien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Mylan bvba/sprl 
Tél/Tel: + 32 (0)2 658 61<br />
Lietuva 
Mylan Healthcare UAB 
Tel: +370 5 205 1 
България 
Майлан ЕООД 
Тел: +359 2 44 55<br />
Luxembourg/Luxemburg 
Mylan bvba/sprl 
Tél/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>Česká republika 
Viatris CZ s.r.o. 
Tel: + 420 222 004 Magyarország 
Mylan EPD Kft. 
Tel.: + 36 1 465 2 </p>
<p>Danmark 
Viatris ApS 
Tlf: +45 28 11 69  </p>
<p>Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01<br />
Deutschland 
Viatris Healthcare GmbH 
Tel: +49 800 0700<br />
Nederland 
Mylan BV 
Tel: + 31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti 
filiaal 
Tel: + 372 6363<br />
Norge 
Viatris AS 
Tlf: + 47 66 75 33  </p>
<p>Ελλάδα 
Generics Pharma Hellas ΕΠΕ 
Τηλ: +30 210 993 6 
Österreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2 
España 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102<br />
Polska 
Mylan Healthcare Sp. z.o.o. 
Tel.: + 48 22 546 64<br />
France 
Viatris Santé 
Tél: +33 4 37 25 75<br />
Portugal 
Mylan, Lda. 
Tel: + 351 214 127<br />
Hrvatska 
Mylan Hrvatska d.o.o. 
Tel: +385 1 23 50<br />
România 
BGP Products SRL 
Tel: + 40 372 579<br />
Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711 
Slovenija 
Viatris d.o.o. 
Tel: +386 1 23 63<br />
Ísland 
Icepharma hf.<br />
Sími: +354 540 8Slovenská republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199<br />
Italia 
Mylan Italia S.r.l. 
Tel: + 39 02 612 46 </p>
<p>Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9 
Κύπρος 
Varnavas Hadjipanayis Ltd 
Τηλ:+357 2220 7 
Sverige 
Viatris AB 
Tel: + 46 (0)8 630 19<br />
Latvija 
Mylan Healthcare SIA 
Tel: +371 676 055<br />
United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711 
Denne indlægsseddel blev senest ændret juni 2022. Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-553de2aa690a5750d1825c26ecd3f9ed
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for gefitinib Package Leaflet for language en"
Description: "ePI document Bundle for gefitinib Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-553de2aa690a5750d1825c26ecd3f9ed"
* entry[0].resource = composition-en-553de2aa690a5750d1825c26ecd3f9ed

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp553de2aa690a5750d1825c26ecd3f9ed"
* entry[=].resource = mp553de2aa690a5750d1825c26ecd3f9ed
                            
                    
Instance: bundlepackageleaflet-da-553de2aa690a5750d1825c26ecd3f9ed
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for gefitinib Package Leaflet for language da"
Description: "ePI document Bundle for gefitinib Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-553de2aa690a5750d1825c26ecd3f9ed"
* entry[0].resource = composition-da-553de2aa690a5750d1825c26ecd3f9ed

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp553de2aa690a5750d1825c26ecd3f9ed"
* entry[=].resource = mp553de2aa690a5750d1825c26ecd3f9ed
                            
                    



Instance: mp553de2aa690a5750d1825c26ecd3f9ed
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Gefitinib Mylan 250 mg film-coated tablets"
Description: "Gefitinib Mylan 250 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1321/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Gefitinib Mylan 250 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 553de2aa690a5750d1825c26ecd3f9edListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "gefitinib"

* status = #current
* mode = #working

* title = "List of all ePIs associated with gefitinib"

* subject = Reference(mp8c06e066675155f873d21c2aba44f835)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#gefitinib "gefitinib"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-553de2aa690a5750d1825c26ecd3f9ed) // gefitinib en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-553de2aa690a5750d1825c26ecd3f9ed) // gefitinib da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-553de2aa690a5750d1825c26ecd3f9ed
InstanceOf: List

* insert 553de2aa690a5750d1825c26ecd3f9edListRuleset
    